Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neurología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation
INTERVENTIONAL
Inicio: 1 de dic de 2006
ID: NCT00403767
Reclutando
ClinicalTrials.gov
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
INTERVENTIONAL
Inicio: 23 de jun de 2021
ID: NCT04701684
Reclutando
ClinicalTrials.gov
Natural History Study of Synucleinopathies
OBSERVATIONAL
Inicio: 1 de jun de 2011
ID: NCT01799915
Terminado
Fase 3
ClinicalTrials.gov
An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)
INTERVENTIONAL
Inicio: 21 de mar de 2022
ID: NCT05211947
Terminado
Fase 3
ClinicalTrials.gov
An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy
INTERVENTIONAL
Inicio: 1 de nov de 2005
ID: NCT00147355
Completado
Fase 2
ClinicalTrials.gov
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01227967
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
INTERVENTIONAL
Inicio: 11 de dic de 2019
ID: NCT04136184
Completado
Fase 3
ClinicalTrials.gov
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria
INTERVENTIONAL
Inicio: 1 de jul de 2006
ID: NCT00421109
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
INTERVENTIONAL
Inicio: 21 de ago de 2024
ID: NCT06290141
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA
INTERVENTIONAL
Inicio: 26 de ene de 2023
ID: NCT05686070
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
INTERVENTIONAL
Inicio: 31 de ago de 2011
ID: NCT01247324
Completado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00549770
Reclutando
Fase 3
ClinicalTrials.gov
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
INTERVENTIONAL
Inicio: 30 de abr de 2025
ID: NCT06952530
Completado
Fase 2
ClinicalTrials.gov
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
INTERVENTIONAL
Inicio: 27 de ene de 2019
ID: NCT03766581
Completado
ClinicalTrials.gov
Betaferon Prospective Study on Adherence, Coping and Nursing Support
OBSERVATIONAL
Inicio: 1 de jun de 2008
ID: NCT00787657
Terminado
Fase 2
ClinicalTrials.gov
A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease
INTERVENTIONAL
Inicio: 6 de mar de 2014
ID: NCT01915303
Activo, no recluta
Fase 3
ClinicalTrials.gov
MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
INTERVENTIONAL
Inicio: 22 de nov de 2024
ID: NCT06672237
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures
INTERVENTIONAL
Inicio: 1 de sept de 2005
ID: NCT00232596
Reclutando
Fase 3
ClinicalTrials.gov
A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)
INTERVENTIONAL
Inicio: 10 de feb de 2026
ID: NCT07201922
Reclutando
Fase 2
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms
INTERVENTIONAL
Inicio: 28 de nov de 2024
ID: NCT06629389
Anterior
1
...
10
11
12
...
434
Siguiente
Filtros